纳武单抗在硅纤维沉积性食管鳞癌化疗中的效果及安全性研究  

Efficacy and safety of opdivo in chemotherapy for silicon fiber enriched esophageal squamous cell carcinoma

作　　者：申丽[1] 李东辉[1] 李杰[1] 王艳伟[1] SHEN Li;LI Donghui;LI Jie;WANG Yanwei(Department of General Surgery,Textile Hospital,Handan First Hospital,Handan 056004,China)

机构地区：[1]邯郸市第一医院纺医院区综合外科,河北邯郸056004

出　　处：《陕西医学杂志》2023年第6期732-736,共5页Shaanxi Medical Journal

基　　金：河北省科技厅重点研发计划项目(172777150)。

摘　　要：目的:探讨细胞程序性死亡-配体1(PD-L1)抑制剂纳武单抗在硅纤维沉积性食管鳞癌化疗中的效果及安全性。方法:选取接受食管癌根治性手术的硅纤维沉积性食管鳞癌患者256例,根据治疗方法的不同分为观察组(132例)和对照组(124例)。两组均给予多西他赛联合奥沙利铂常规化疗方案,同时观察组联合应用纳武单抗治疗。比较两组治疗效果、血清肿瘤标志物、不良反应发生情况、3年无进展生存率及总生存率。结果:观察组总有效率高于对照组(P<0.05)。化疗后,两组血清癌胚抗原(CEA)、糖类抗原199(CA199)、鳞状细胞癌抗原(SCC)水平低于化疗前,且观察组低于对照组(均P<0.05)。无论是化疗1个周期后还是化疗100 d后,观察组不良反应发生率与对照组比较差异无统计学意义(均P>0.05)。观察组3年无进展生存率和总生存率高于对照组(均P<0.05)。结论:硅纤维沉积性食管鳞癌根治术后,在多西他赛联合奥沙利铂方案中增加纳武单抗可以提高疗效和患者生存率,且具有临床安全性。Objective:To investigate the efficacy and safety of programmed cell death 1 ligand 1(PD-L1)inhibitor opdivo in chemotherapy for silicon fiber enriched esophageal squamous cell carcinoma.Methods:A total of 256 cases of patients with silicon fiber enriched esophageal squamous cell carcinoma who underwent radical surgery were selected and divided into observation group(132 cases)and control group(124 cases)according to different treatment methods.Both groups were given docetaxel combined with oxaliplatin conventional chemotherapy regimen,and the observation group was given opdivo additionally.The therapeutic effect,serum tumor markers,occurrence of adverse reactions,3-year progression-free survival rate and overall survival rate were compared between the two groups.Results:The total effective rate of observation group was higher than that of control group(P<0.05).After chemotherapy,the CEA,CA199 and SCC levels in two groups were lower than those before chemotherapy,and the observation group was lower than control group(all P<0.05).No matter after 1 cycle or 100 d of chemotherapy,there was no significant difference in the incidence of adverse reactions between two groups(all P>0.05).The 3-year progression-free survival rate and overall survival rate in observation group were higher than those in control group(both P<0.05).Conclusion:After radical surgery for silicon fiber enriched esophageal squamous cell carcinoma,adding opdivo to docetaxel combined with oxaliplatin can improve the efficacy and survival rate of patients,and is clinically safe.

关 键 词：硅纤维沉积性食管鳞癌 纳武单抗 细胞程序性死亡-配体1 生存率 不良反应 安全性 

分 类 号：R735.1[医药卫生—肿瘤]